HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy
Authors:
Open Access
- 26 August 2014
- journal article
- early detection-and-diagnosis
- Published by Wiley in International Journal of Cancer
- Vol. 136 (7) , 1629-1635
Abstract
Growth factor receptors, often carrying tyrosine kinase activities in their cytoplasmic domains, are overexpressed in many cancers. Coactivation of receptor tyrosine kinases (RTKs) plays a critical role in tumor response to targeted therapeutics. We examined concomitant overexpression of EGFR and MET in patients with HER2+ and HER2− gastric cancers (GCs). Tissue microarray samples obtained from 1,589 GC patients who received R0 gastrectomy with extensive node dissection and adjuvant chemoradiationtherapy were analyzed by immunohistochemistry and fluorescence in situ hybridization. HER2+ was observed in 169 patients (11%). Out of 169 HER2+ patients, 15 (9%) were EGFR+ and MET+, 29 (17%) were EGFR+, 37 (22%) were MET+ and the remaining 88 patients (52%) were HER2+ only, without concomitant EGFR or MET overexpression. Greater number of overexpressed RTKs correlated with younger age (p < 0.001), larger tumor size (p = 0.027), intestinal histology (p < 0.001) and shorter overall survival (p = 0.002). The mean overall survival was 113 months for HER2−/EGFR−/MET− and 63 months for HER2+/EGFR+/MET+ subgroups. Patients with HER2+/EGFR+/MET+ GCs had a substantial risk of death with a hazard ratio of 3.01 (95% CI: 1.54–5.90), compared with HER2−/EGFR−/MET− GC patients. Using patient‐derived tumor cell models isolated from pericardial effusion of HER2+ and MET+ GC cases, we demonstrated that the combination of HER2‐inhibitor (lapatinib) and MET‐inhibitor offered a more profound inhibition in the ERK/AKT pathway and cell proliferation than lapatinib alone. Co‐overexpression of RTKs was demonstrated in small subsets of GC associated with aggressive behavior and in these cases, combination therapy may be considered as potential treatment options.Keywords
This publication has 29 references indexed in Scilit:
- Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma CellsClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer CellsCancer Research, 2010
- Receptor Tyrosine Kinase Coactivation Networks in CancerCancer Research, 2010
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating MutationsCancer Research, 2008
- HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cellsMolecular Cancer Therapeutics, 2008
- Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancerBritish Journal of Cancer, 2008
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung CancerClinical Cancer Research, 2008
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer CellsCancer Research, 2008
- Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted TherapiesScience, 2007